Form 8-K - Current report:
SEC Accession No. 0000950170-22-019610
Filing Date
2022-10-17
Accepted
2022-10-17 16:55:11
Documents
13
Period of Report
2022-10-13
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalv-20221013.htm   iXBRL 8-K 97775
2 EX-99.1 kalv-ex99_1.htm EX-99.1 17494
  Complete submission text file 0000950170-22-019610.txt   238619

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kalv-20221013.xsd EX-101.SCH 2469
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kalv-20221013_pre.xml EX-101.PRE 9843
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kalv-20221013_lab.xml EX-101.LAB 13360
7 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20221013_htm.xml XML 4718
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 221314167
SIC: 2834 Pharmaceutical Preparations